Compositions for the treatment of rheumatoid arthritis and methods of using same
AssigneesSanofi Biotechnology, Regeneron Pharmaceuticals, Inc.
InventorsXiaohong Huang, Martine Jasson, Vanessa Marks, Allen Radin
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R) with a DMARD.
Claims30
A method of treating rheumatoid arthritis in a subject previously ineffectively treated by administering methotrexate, the method comprising subcutaneously administering to the subject about 150 mg to about 200 mg of an antibody once every two weeks, wherein the antibody comprises a heavy chain variable region (VH) comprising the three complementarity determining regions (CDRs) of SEQ ID NO:2, and a light chain variable region (VL) comprising the three CDRs of SEQ ID NO:3.
(canceled)
(canceled)
(canceled)
12-17. (canceled)
A method of treating rheumatoid arthritis in a subject previously ineffectively treated by administering methotrexate, the method comprising subcutaneously administering to the subject about 150 mg of an antibody once every two weeks, wherein the antibody comprises a heavy chain variable region (VH) comprising the three complementarity determining regions (CDRs) of SEQ ID NO:2, and a light chain variable region (VL) comprising the three CDRs of SEQ ID NO:3, and wherein the subject achieves at least a 20% improvement in the American College of Rheumatology core set disease index after treatment.
A method of treating rheumatoid arthritis in a subject previously ineffectively treated by administering methotrexate, the method comprising subcutaneously administering to the subject 200 mg of an antibody once every two weeks, wherein the antibody comprises a heavy chain variable region (VH) comprising the three complementarity determining regions (CDRs) of SEQ ID NO:2, and a light chain variable region (VL) comprising the three CDRs of SEQ ID NO:3, and wherein the subject achieves at least a 20% improvement in the American College of Rheumatology core set disease index after treatment.
Dependencies are inferred from the claim text.